Company Overview and News

 
 
Draining The Swamp: How The St. Joe Company Has Evolved Into The Ultimate Real Estate Moat

2018-05-18 seekingalpha
Began purchasing shares of St. Joe (JOE) in mid-2017 as it became clear the Company was finally in position to fully capitalize on the inherent value of its assets.

 
SpeedNews Defense & Space

2018-05-18 aviationweek
GENERAL ATOMICS AERONAUTICAL SYSTEMS INC. has $206m U.S. Air Force contract to retrofit 122 MQ-9 Block 5 aircraft. AURORA FLIGHT SCIENCES CORP. and the Office of Naval Research received Howard Hughes innovation award from the American Helicopter Society for their joint work on Autonomous Aerial Cargo Utility System (AACUS). AVIC of China completed airborne weapon firing tests of Z-19E armed helicopter.

 
SpeedNews Defense & Space

2018-05-18 aviationweek
GENERAL ATOMICS AERONAUTICAL SYSTEMS INC. has $206m U.S. Air Force contract to retrofit 122 MQ-9 Block 5 aircraft. AURORA FLIGHT SCIENCES CORP. and the Office of Naval Research received Howard Hughes innovation award from the American Helicopter Society for their joint work on Autonomous Aerial Cargo Utility System (AACUS). AVIC of China completed airborne weapon firing tests of Z-19E armed helicopter.

 
Tracking Bill Ackman's Pershing Square Portfolio - Q1 2018 Update

2018-05-16 seekingalpha
The largest three 13F positions are Restaurant Brands International, Chipotle Mexican Grill, and Automatic Data Processing and together they account for around two-thirds of the portfolio.

 
HHC / Howard Hughes Corp. (The) - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-09 fintel.io
Howard Hughes Corp. (The) (NYSE:HHC) has 265 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 38,194,361 shares. Largest shareholders include Pershing Square Capital Management, L.P., Vanguard Group Inc, Horizon Kinetics LLC, Harris Associates L P, Baillie Gifford & Co, BlackRock Inc., Citigroup Inc, Nomura Holdings Inc, Principal Financial Group Inc, and UBS Group AG.

 
HHC / Howard Hughes Corp. (The) / VANGUARD GROUP INC - null (Passive Investment)

2018-05-09 sec.gov
howardhughescorpthe.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
HHC / Howard Hughes Corp. (The) / VANGUARD GROUP INC - null (Passive Investment)

2018-05-09 sec.gov
howardhughescorpthe.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
Howard Hughes 2017 Annual Review

2018-05-03 seekingalpha

 
Howard Hughes Corp's (HHC) CEO David Weinreb on Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
The Howard Hughes Corporation (NYSE:HHC) Q1 2018 Earnings Conference Call May 2, 2018 11:00 AM ET

 
The Howard Hughes Corporation 2018 Q1 - Results - Earnings Call Slides

2018-05-02 seekingalpha
The following slide deck was published by The Howard Hughes Corporation in conjunction with their 2018 Q1 earnings call.

1
HHC / Howard Hughes Corp. (The) 8-K (Current Report)

2018-05-01 sec.gov
Document UNITED STATES

 
Kanye West praises this generation’s Steve Jobs and Walt Disney: himself - MarketWatch

2018-04-25 marketwatch
There’s a lot to unpack in Kanye West’s busy Twitter feed this week. Apparently, he’s still running for president in 2024, he dumped his manager, he’s hiring some 160 people, he makes more money on shoes than Michael Jordan and his Yeezy brand is “a unicorn on its way to being a decacorn.”

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 44267D107